Menopause & Weight Loss
Can Wegovy Help Menopause Weight Gain?
Quick Answer: Yes — Wegovy (semaglutide 2.4 mg) can be an effective treatment for menopause-related weight gain. It addresses several of the key biological drivers including amplified hunger signalling, increasing insulin resistance and appetite dysregulation driven by declining hormones. Clinical trial data shows average weight loss of approximately 15% of body weight over 68 weeks.15%average weight loss at 68 weeks (STEP 1 trial)
1.5 kgaverage annual weight gain during the menopausal transition
3×greater visceral fat risk post-menopause vs pre-menopause
The Biology
Why Menopause Causes Weight Gain
Menopausal weight gain is not simply a consequence of eating more or moving less. The fundamental driver is a profound shift in the body's hormonal environment that affects where fat is stored, how efficiently calories are metabolised, and how effectively hunger and fullness signals are processed.
As oestrogen declines, fat redistributes from hips and thighs to the abdomen — the dangerous visceral fat that surrounds internal organs. Resting metabolic rate also declines, meaning a woman at 50 may require 200–300 fewer calories per day to maintain the same weight she carried at 35. Insulin resistance increases progressively, and sleep disruption from hot flushes elevates cortisol and hunger hormones further.
The Menopausal Weight Trap: The convergence of declining oestrogen (redistributing fat to the abdomen), reduced metabolic rate (requiring fewer calories), increasing insulin resistance (promoting fat storage) and disrupted sleep (amplifying hunger hormones) creates a perfect storm for weight gain. Addressing only one of these factors through diet or exercise is rarely sufficient.
Why Traditional Diets Often Fail During Menopause
| Myth | Fact |
|---|---|
| Eat less, lose weight — it is that simple | Hormonal changes alter fat distribution, metabolic rate and appetite signalling independently of calorie intake |
| Exercise enough and you can outrun menopausal weight gain | Exercise supports health but is insufficient as a solo intervention against the hormonal drivers of menopausal weight gain |
| Calorie restriction works for everyone regardless of hormones | Severe calorie restriction triggers adaptive thermogenesis — the body reduces metabolic rate further, making sustained restriction progressively less effective |
| Weight gain during menopause is inevitable | Meaningful weight loss during menopause is achievable with appropriate support — STEP 1 data (mean age 46, majority female) shows average 15% loss |
Clinical Evidence
What the STEP 1 Trial Shows for Menopausal Women
The STEP 1 trial enrolled 1,961 adults with a mean participant age of 46 years — the majority female, with a substantial proportion likely to be in perimenopause or post-menopause. Participants receiving semaglutide 2.4 mg achieved average weight loss of 14.9% of body weight, with significant reductions in waist circumference (averaging 13.54 cm), blood pressure and markers of metabolic health.
Can Wegovy and HRT be taken together?
There is no known pharmacokinetic interaction between semaglutide and HRT (whether oestrogen-only, combined oestrogen/progestogen, or testosterone-containing preparations). Women currently taking HRT who meet the eligibility criteria for Wegovy may be prescribed both concurrently. The decision should be made in consultation with your prescribing clinician.
HRT does not cause significant weight loss in most women, but it may help to partially reverse the abdominal fat redistribution driven by declining oestrogen. Wegovy and HRT address different aspects of the menopausal metabolic picture and are not mutually exclusive.
| Outcome | Semaglutide 2.4 mg | Placebo | Relevance to Menopausal Women |
|---|---|---|---|
| Mean weight loss | 14.9% | 2.4% | Clinically meaningful reduction across age groups |
| Waist circumference | −13.54 cm | −4.13 cm | Directly targets menopausal visceral fat accumulation |
| Systolic blood pressure | −6.16 mmHg | −1.06 mmHg | Relevant as CVD risk rises post-menopause |
| Achievement of ≥5% loss | 86% of participants | 32% | Most patients achieve clinically meaningful loss |
FAQs
Frequently Asked Questions
Yes. The STEP 1 trial — conducted predominantly in women with a mean age of 46 — demonstrates average weight loss of approximately 15% of body weight over 68 weeks. Wegovy's mechanism of action directly addresses key drivers of menopausal weight gain including insulin resistance, appetite dysregulation and visceral fat accumulation.
The combination of declining oestrogen (which drives fat redistribution to the abdomen), reduced metabolic rate, increasing insulin resistance and disrupted sleep creates a physiological environment in which the same dietary effort produces fewer results than before menopause — through no fault of the individual. Wegovy addresses several of these biological barriers simultaneously.
Yes. There is no known pharmacokinetic interaction between semaglutide and HRT. Women currently taking HRT who meet Wegovy's eligibility criteria can be prescribed both, subject to clinical assessment.
Weight loss on Wegovy includes a meaningful reduction in visceral abdominal fat. STEP 1 participants experienced average waist circumference reductions of 13.54 cm. This targeted reduction in visceral fat is particularly significant for menopausal women, given that this fat type is independently associated with increased cardiovascular and metabolic risk.
Women can expect broadly similar results to the overall STEP 1 trial: modest loss in the first four weeks, 5–7% by three months and 10% or more by six months. Women in active perimenopause may find their trajectory is slightly less linear, with plateaus corresponding to hormonal shifts.
Yes. Post-menopausal women who meet the clinical eligibility criteria for Wegovy may be prescribed it following assessment. Post-menopausal women have typically completed the most turbulent phase of hormonal transition, which can actually make the weight loss trajectory on Wegovy more predictable and consistent than during perimenopause.
Ready to Start Wegovy Treatment?
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment
Check Your Eligibility →
Wilding JPH et al. STEP 1. N Engl J Med. 2021. Thurston RC et al. Maturitas. 2016. NICE TA875. 2023. MHRA. 2023. Happy Pharmacy (GPhC No. 9012585). Educational purposes only — not medical advice.